When was Comanche founded?

Comanche was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Comanche located?

Comanche is headquartered in Concord, United States.

Who is the current CEO of Comanche?

T Scott Johnson of Comanche. They have also founded 1 company.

How many employees does Comanche have?

As of Mar 01, 2026, the latest employee count at Comanche is 10 - 49.

Is Comanche a funded company?

Comanche is a funded company, having raised a total of $111M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 28, 2021.

When was the latest funding round of Comanche?

Comanche's latest funding was a $***** Series B round on Jan 17, 2024, with participation from 6 investors.

Where does Comanche rank among its competitors?

Comanche ranks 14th amongst 70 active competitors, of which 25 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was City Therapeutics, which secured $99.5M in Jun, 2026.

Who are the top competitors of Comanche?

Comanche's top competitors include Alnylam, Sirnaomics and Avidity Biosciences. Among them, City Therapeutics secured the most recent funding round in June, 2026.

Comanche - 2026 Company Profile, Team, Funding & Competitors

Comanche is a series B company based in Concord (United States), founded in 2020 by T Scott Johnson. It operates as a Developer of RNA therapeutics to treat preeclampsia. Comanche has raised $111M in funding from investors like New Enterprise Associates, Atlas Venture and Google Ventures. The company has 70 active competitors, including 25 funded and 22 that have exited. Its top competitors include companies like Alnylam, Sirnaomics and Avidity Biosciences.

Company Details

Developer of RNA therapeutics to treat preeclampsia. The company is developing siRNA compounds that are capable of silencing the sFLT-1 gene in the placenta to halt the production of the protein responsible for preeclampsia.

Key Metrics

Founded Year

2020

Location

Concord, United States

Stage

Series B

Total Funding

$111M in 2 rounds

Latest Funding Round

Series B, Jan 17, 2024, $*****

Investors

New Enterprise Associates & 6 more

Ranked

14^th among 70 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Alnylam & 91 more

View Comanche's full profile

Comanche has raised a total funding of $111M over 2 rounds. Its first funding round was on Jun 28, 2021. Its latest funding round was a Series B round on Jan 17, 2024 for $*****. 6 investors participated in its latest round. Comanche has 7 institutional investors.

Here is the list of recent funding rounds of Comanche:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 17, 2024	5176187	Series B	8101597	3958932	3540363	3319295
Jun 28, 2021	1378957	Series A	6218450	8962691	1770706	8096104

Access funding benchmarks and valuations. Sign up today!

View details of Comanche's funding rounds and investors

The founders of Comanche is T Scott Johnson. T Scott Johnson is the CEO of Comanche.

Here are the details of Comanche's key team members:

T Scott Johnson: Co-Founder and CEO of Comanche.

View details of Comanche's Founder profiles and Board Members

Comanche's employee count trend

Comanche has 10 - 49 employees as of Mar 26. Here is Comanche's employee count trend over the years:

Uncover Comanche's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Comanche include Alnylam, Sirnaomics and Avidity Biosciences. Here is the list of Top 10 competitors of Comanche, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Lilly & 20 others	66/100
4th	City Therapeutics 2006, Cambridge (United States), Series B	Developer of gene therapies for multiple diseases	$234M	Arch Venture Partners, Sofinnova Investments ... & 9 others	63/100
5th	Arrowhead Pharmaceuticals 1989, Pasadena (United States), Acquired	Developer of therapeutics to treat multiple diseases	$60M	Colt Ventures, Amgen Business Development ... & 8 others	62/100
6th	OliX Pharmaceuticals 2010, Suwon-si (South Korea), Public	Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.	-	IMM Investment, Kolon Investments & 16 others	61/100
7th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	Domain Associates, RA Capital Management ... & 18 others	60/100
8th	Souzhou Ribo Life Science 2007, Suzhou (China), Public	Developer of nucleic acid drugs based on RNA interference (RNAi) technology	$201M	Panlin Capital, SDIC Innovation & 13 others	60/100
9th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$114M	Decheng Capital, Mayfield & 10 others	59/100
10th	Arbutus Bio 1992, Burnaby (Canada), Public	Developer of nucleic acid-based therapeutics	$10M	Foresite Capital, Roivant Sciences & 4 others	59/100
14th	Comanche 2020, Concord (United States), Series B	Developer of RNA therapeutics to treat preeclampsia	$111M	Atlas Venture, F-Prime Capital & 5 others	54/100